Combined Effect of Omega-3 Fatty Acid and Vitamin D 3 on Oxidized LDL-C and Non-HDL-C Levels in People With Vitamin D Deficiency: A Randomized Controlled Trial.
Journal
Journal of cardiovascular pharmacology
ISSN: 1533-4023
Titre abrégé: J Cardiovasc Pharmacol
Pays: United States
ID NLM: 7902492
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
received:
07
02
2022
accepted:
16
12
2022
medline:
11
4
2023
pubmed:
12
1
2023
entrez:
11
1
2023
Statut:
epublish
Résumé
The present randomized clinical trial (RCT) was conducted on Jordanian participants with vitamin D deficiency (VDD) with no other medical conditions, to evaluate the combined effect of 1,25-dihydroxy vitamin D 3 (Vit.D 3 ) and omega-3 fatty acid (n-3FA) supplements (D+) on oxidized low-density lipoprotein (Ox-LDL) and non-high-density lipoprotein cholesterol (non-HDL-C) levels as common predictors of cardiovascular diseases (CVDs). Participants were randomized into 4 groups as follows: a control group (C) that received no supplementations, a Vit.D 3 group that received 50,000 IU of Vit.D 3 every week, an n-3FA group that received 300 mg of omega-3 fatty acid every day, and a D+ group that received a combination of both supplements, with the same dosage administered by the previous groups but with a 4-6-hour time interval between Vit.D 3 and n-3FA administration to avoid any possible interaction. All supplementations were administered orally for 8 weeks. Forty-seven participants were allocated to each group. Twenty-six in the control group, 37 participants in the Vit.D 3 group, 37 participants in the n-3FA group, and 46 participants in the D+ group completed the study to the end. The D+ supplementations significantly increased non-HDL-C (118.99 ± 60.98 to 155.26 ± 43.36 mg/dL, P << 0.05) but decreased Ox-LDL-C levels (69.29 ± 37.69 to 52.81 ± 17.30 pg/mL, P = 0.03). The stepwise regression showed that the serum LDL-C level was the main independent variable involved in the elevation of non-HDL levels (R 2 = 0.837) observed at the end of the trial in the D+ group. The groups that were supplemented with either Vit.D 3 alone or n-3FA alone had an insignificant decrease in the level of Ox-LDL-C. In conclusion, despite the observed hyperlipidemic effect, the combination treatment is recommended by the research team because the decrease in Ox-LDL may offset the hyperlipidemic effect.
Identifiants
pubmed: 36630694
doi: 10.1097/FJC.0000000000001398
pii: 00005344-202304000-00003
doi:
Substances chimiques
oxidized low density lipoprotein
0
Fatty Acids, Omega-3
0
Cholecalciferol
1C6V77QF41
Lipoproteins, LDL
0
Cholesterol
97C5T2UQ7J
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
251-258Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Palacios C, Gonzalez L. Is vitamin D deficiency a major global public health problem? J Steroid Biochem Mol Biol. 2014;144:138–145. oi:
Abu-Samak MS, AbuRuz ME, Masa'Deh R, et al. Correlation of selected stress associated factors with vitamin D deficiency in Jordanian men and women. Int J Gen Med. 2019; 12:225–233. PMID: 31303782; PMCID: PMC6612048.
Ruz MEA, Momani A, Shajrawi AA. Vitamin D mediates the relationship between depressive symptoms and quality of life among patients with heart failure. J Cardiovasc Nurs. 2021;36:185–192. PMID: 32740223.
Hewison M. An update on vitamin D and human immunity. Clin Endocrinol (Oxf). 2012;76:315–325.
Shirazi L, Almquist M, Borgquist S, et al. Serum vitamin D (25OHD3) levels and the risk of different subtypes of breast cancer: a nested case-control study. Breast. 2016; 28:184–190.
Mozos I, Marginean O. Links between vitamin D deficiency and cardiovascular diseases. Biomed Res Int. 2015; 2015:1–12.
Kunadian V, Ford GA, Bawamia B, et al. Vitamin D deficiency and coronary artery disease: a review of the evidence. Am Heart J. 2014;167:283–291.
Lupton JR, Faridi KF, Martin SS, et al. Deficient serum 25-hydroxyvitamin D is associated with an atherogenic lipid profile: the Very Large Database of Lipids (VLDL-3) study. J Clin Lipidol. 2016;10:72.e1–81.e1.
Petri Nahas EA, Poloni PF, Nahas-Neto J, et al. Vitamin D deficiency is associated with metabolic syndrome in postmenopausal women. Maturitas. 2018; 107:97–102.
Pilz S, Verheyen N, Grübler MR, et al. Vitamin D, and cardiovascular disease prevention. Nat Rev Cardiol. 2016 ;13 :404–417.
Seibert E, Lehmann U, Riedel A, et al. Vitamin D 3 supplementation does not modify cardiovascular risk profile of adults with inadequate vitamin D status. Eur J Nutr. 2017;56:621–634.
Sondarwa K, Buttar RS, Hensley V, et al. Vitamin D and cardiovascular disease. Contemp EndocrAinol. 2018; 4648:151–164.
Dror Y, Giveon SM, Hoshen M, et al. Vitamin D levels for preventing acute coronary syndrome and mortality: evidence of a nonlinear association. J Clin Endocrinol Metab. 2013 ;98:2160–2167.
Kita T, Kume N, Minami M, et al. Role of oxidized LDL in atherosclerosis. Ann NY Acad Sci. 2006 ;947 :199–206;discussion 205-206.
Holvoet P, Mertens A, Verhamme P, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2001;21:844–848.
Spieker LE, Lüscher TF. Protection of endothelial function. Handbook Exp Pharmacol. 2005;(170):619–644.
Suades R, Padró T, Alonso R, et al. Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets, and inflammatory cells. Thromb Haemost. 2013;110:366–377.
Mohamad MI, El-Sherbeny EE, Bekhet MM. The effect of vitamin D supplementation on glycemic control and lipid profile in patients with type 2 diabetes mellitus. J Am Coll Nutr. 2016;35:399–404.
Farag HAM, Hosseinzadeh-Attar MJ, Muhammad BA, et al. Effects of vitamin D supplementation along with endurance physical activity on lipid profile in metabolic syndrome patients: a randomized controlled trial. Diabetes Metab Syndr Clin Res Rev. 2019;13:1093–1098.
Zhao LS, Wang H, Yin DW, et al. Effects of vitamin D on plasma lipid profiles in statin-treated patients with hypercholesterolemia: a randomized placebo-controlled trial. Clin Nutr. 2015;34:201–206.
Orchard TS, Pan X, Cheek F, et al. A systematic review of omega-3 fatty acids and osteoporosis. Br J Nutr. 2012;107:S253–S260.
Yashodhara BM, Umakanth S, Pappachan JM, et al. Omega-3 fatty acids: a comprehensive review of their role in health and disease. Postgrad Med J. 2009;85:84–90.
Schwetz V, Scharnagl H, Trummer C, et al. Vitamin D supplementation and lipoprotein metabolism: a randomized controlled trial. J Clin Lipidol. 2018;12:588.e4–596.e4. Epub 2018 Mar 15. PMID: 29653812.
Challoumas D, Vitamin D supplementation and lipid profile: what does the best available evidence show? Atherosclerosis. 2014;235:130–139.
Manson JE, Cook NR, Lee I-M, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019;380:33–44.
Güttler N, Zheleva K, Parahuleva M, et al. Omega-3 fatty acids and vitamin D in cardiology. Cardiol Res Pract. 2012; 2012:1–11.
Bergmann K. Non-HDL cholesterol and evaluation of cardiovascular disease risk. Ejifcc. 2010;21:64–67.
Ponda MP, Dowd K, Finkielstein D, et al. The short-term effects of vitamin d repletion on cholesterol: a randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol. 2012;32:2510–2515.
Richardson AJ, Burton JR, Sewell RP, et al. Docosahexaenoic acid for reading, cognition and behavior in children aged 7-9 years: a randomized, controlled trial (the DOLAB Study). PLoS One. 2012;7: e43909. Epub 2012 Sep 6. PMID: 22970149; PMCID: PMC3435388.
Dastorani M, Aghadavod E, Mirhosseini N, et al. The effects of vitamin D supplementation on metabolic profiles and gene expression of insulin and lipid metabolism in infertile polycystic ovary syndrome candidates for in vitro fertilization. Reprod Biol Endocrinol. 2018;16:94–97.
Salekzamani S, Mehralizadeh H, Ghezel A, et al. Effect of high-dose vitamin D supplementation on cardiometabolic risk factors in subjects with metabolic syndrome: a randomized controlled double-blind clinical trial. J Endocrinol Invest. 2016;39:1303–1313.
Ross AC, Taylor CL, Yaktine AL, et al eds. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Dietary reference Intakes for calcium and vitamin D. Washington, DC: National Academies Press; 2011.
Shapses SA, Manson JE. Vitamin d and prevention of cardiovascular disease and diabetes: why the evidence falls short. JAMA 2011; 305:2565–2566.
Zittermann A. Vitamin D and cardiovascular disease. Anticancer Res. 2014;34:4641–4648.
Towler DA. Calciotropic hormones and arterial physiology: “D”-lightful insights. J Am Soc Nephrol. 2007; 18:369–373.
Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002 ;106:2747–2757.
Christen W, Sc D, Bassuk SS, et al. Marine n−3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2018:1–10.
The ASCEND Study Collaborative Group. Effects of n−3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018; 379:1540–1550.
Aung T, Halsey J, Kromhout D, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. JAMA Cardiol. 2018; 3:225–234.
Bhatt DL, Steg PG, Miller M, et al.; REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22. Epub 2018 Nov 10. PMID: 30415628.
Chang CH, Tseng PT, Chen NY, et al. Safety and tolerability of prescription omega-3 fatty acids: a systematic review and meta-analysis of randomized controlled trials. Prostaglandins Leukot Essent Fatty Acids 2018; 129:1–12.
Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324:2268–2280. PMID: 33190147; PMCID: PMC7667577.
Bernstein AM, Ding EL, Willett WC, et al. A meta-analysis shows that docosahexaenoic acid from algal oil reduces serum triglycerides and increases HDL-cholesterol and LDL-cholesterol in persons without coronary heart disease. J Nutr. 2012 ;142:99–104.
Moeinzadeh F, Shahidi S, Mortazavi M, et al. Effects of Omega-3 fatty acid supplementation on serum biomarkers, inflammatory agents, and quality of life of patients on hemodialysis. Iran J Kidney Dis. 2016;10:381–387.
Abellán R, Mansego ML, Martínez-Hervás S, et al. Dietary polyunsaturated fatty acids may increase plasma LDL-cholesterol and plasma cholesterol concentrations in carriers of an ABCG1 gene single nucleotide polymorphism: study in two Spanish populations. Atherosclerosis. 2011 ;219:900–906.
Calder PC, Laviano A, Lonnqvist F, et al. Targeted medical nutrition for cachexia in chronic obstructive pulmonary disease: a randomized, controlled trial. J Cachexia Sarcopenia Muscle. 2018;9:28–40.
Talari HR, Najafi V, Raygan F, et al. Long-term Vitamin D and high-dose n-3 fatty acids' supplementation improve markers of cardiometabolic risk in type 2 diabetic patients with CHD. Br J Nutr. 2019 ;122:423–430. doi :
Jamilian M, Samimi M, Ebrahimi FA, et al. The effects of vitamin D and omega-3 fatty acid co-supplementation on glycemic control and lipid concentrations in patients with gestational diabetes. J Clin Lipidol. 2017;11:459–468.
Poznyak AV, Nikiforov NG, Markin AM, et al. Overview of OxLDL and its impact on cardiovascular health: focus on atherosclerosis. Front Pharmacol. 2021; 11:613780. PMID: 33510639; PMCID: PMC7836017.
Gajos G, Zalewski J, Mostowik M, et al. Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A2 in patients with stable angina. Nutr Metab Cardiovasc Dis. 2014;24:434–439.
Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis. 2015;242:357–366.
Mason RP. New insights into mechanisms of action for omega-3 fatty acids in atherothrombotic cardiovascular disease. Curr Atheroscler Rep. 2019;21:2.
Sezai A, Unosawa S, Taoka M, et al. Long-term comparison of ethyl icosapentate vs. omega-3-acid ethyl in patients with cardiovascular disease and hypertriglyceridemia (DEFAT trial). Circ J. 83, 2019:1368–1376.
Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129–2138.
Shashkin P, Dragulev B, Ley K. Macrophage differentiation to foam cells. Curr Pharm Des. 2005;11:3061–3072.
Li D, Mehta JL. Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells. Arteriosclerosis, Thromb Vasc Biol. 2000;20:1116–1122.
Dunn S, Vohra RS, Murphy JE, et al. The lectin-like oxidized low-density-lipoprotein receptor: a pro-inflammatory factor in vascular disease. Biochem J. 2008;409:349–355.
Mertens AN, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J. 2001;15:2073–2084.
García-Heredia A, Marsillach J, Rull A, et al. Paraoxonase-1 inhibits oxidized low-density lipoprotein-induced metabolic alterations and apoptosis in endothelial cells: a nondirected metabolomic study. Mediators Inflamm. 2013;2013:156053.
Franczyk B, Rysz J, Ławiński J, et al. Is a high HDL-cholesterol level always beneficial? Biomedicines. 2021;9:1083.
Rosenson RS, Brewer HB Jr, Ansell B, et al. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation. 2013;128:1256–1267.
Mascarenhas-Melo F, Sereno J, Teixeira-Lemos E, et al. Implication of low HDL-c levels in patients with average LDL-c levels: a focus on oxidized LDL, large HDL subpopulation, and adiponectin. Mediators Inflamm. 2013, 2013;1, 12,